-
Something wrong with this record ?
Inhibition of in vitro leukotriene B4 biosynthesis in human neutrophil granulocytes and docking studies of natural quinones
P. Landa, Z. Kutil, V. Temml, J. Malik, L. Kokoska, U. Widowitz, M. Pribylova, M. Dvorakova, P. Marsik, D. Schuster, R. Bauer, T. Vanek,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23472470
Knihovny.cz E-resources
- MeSH
- Anti-Inflammatory Agents analysis MeSH
- Benzoquinones pharmacology MeSH
- Quinones pharmacology MeSH
- Cyclooxygenase 2 Inhibitors analysis MeSH
- Lipoxygenase Inhibitors analysis MeSH
- Plants, Medicinal chemistry MeSH
- Leukotriene B4 antagonists & inhibitors biosynthesis MeSH
- Humans MeSH
- Neutrophils drug effects metabolism MeSH
- Drug Evaluation, Preclinical MeSH
- Plant Extracts chemistry pharmacology MeSH
- Molecular Docking Simulation MeSH
- Thymol analogs & derivatives pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Quinones are compounds frequently contained in medicinal plants used for the treatment of inflammatory diseases. Therefore, the impact of plant-derived quinones on the arachidonic acid metabolic pathway is worthy of investigation. In this study, twenty-three quinone compounds of plant origin were tested in vitro for their potential to inhibit leukotriene B4 (LTB4) biosynthesis in activated human neutrophil granulocytes with 5-lipoxygenase (5-LOX) activity. The benzoquinones primin (3) and thymohydroquinone (4) (IC50 = 4.0 and 4.1 microM, respectively) showed activity comparable with the reference inhibitor zileuton (1C50 = 4.1 microM). Moderate activity was observed for the benzoquinone thymoquinone (2) (1C50 = 18.2 microM) and the naphthoquinone shikonin (1) (IC50 = 24.3 microM). The anthraquinone emodin and the naphthoquinone plumbagin (5) displayed only weak activities (IC50 > 50 microM). The binding modes of the active compounds were further evaluated in silico by molecular docking to the human 5-LOX crystal structure. This process supports the biological data and suggested that, although the redox potential is responsible for the quinone's activity on multiple targets, in the case of 5-LOX the molecular structure plays a vital role in the inhibition. The obtained results suggest primin as a promising compound for the development of dual COX-2/5-LOX inhibitors.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13023941
- 003
- CZ-PrNML
- 005
- 20130710100814.0
- 007
- ta
- 008
- 130703s2013 xxu f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)23472470
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Landa, Premysl $u Laboratory of Plant Biotechnologies, Institute of Experimental Botany AS CR, v.v.i., 165 02 Prague 6 - Lysolaje, Czech Republic. landa@ueb.cas.cz
- 245 10
- $a Inhibition of in vitro leukotriene B4 biosynthesis in human neutrophil granulocytes and docking studies of natural quinones / $c P. Landa, Z. Kutil, V. Temml, J. Malik, L. Kokoska, U. Widowitz, M. Pribylova, M. Dvorakova, P. Marsik, D. Schuster, R. Bauer, T. Vanek,
- 520 9_
- $a Quinones are compounds frequently contained in medicinal plants used for the treatment of inflammatory diseases. Therefore, the impact of plant-derived quinones on the arachidonic acid metabolic pathway is worthy of investigation. In this study, twenty-three quinone compounds of plant origin were tested in vitro for their potential to inhibit leukotriene B4 (LTB4) biosynthesis in activated human neutrophil granulocytes with 5-lipoxygenase (5-LOX) activity. The benzoquinones primin (3) and thymohydroquinone (4) (IC50 = 4.0 and 4.1 microM, respectively) showed activity comparable with the reference inhibitor zileuton (1C50 = 4.1 microM). Moderate activity was observed for the benzoquinone thymoquinone (2) (1C50 = 18.2 microM) and the naphthoquinone shikonin (1) (IC50 = 24.3 microM). The anthraquinone emodin and the naphthoquinone plumbagin (5) displayed only weak activities (IC50 > 50 microM). The binding modes of the active compounds were further evaluated in silico by molecular docking to the human 5-LOX crystal structure. This process supports the biological data and suggested that, although the redox potential is responsible for the quinone's activity on multiple targets, in the case of 5-LOX the molecular structure plays a vital role in the inhibition. The obtained results suggest primin as a promising compound for the development of dual COX-2/5-LOX inhibitors.
- 650 _2
- $a antiflogistika $x analýza $7 D000893
- 650 _2
- $a benzochinony $x farmakologie $7 D016227
- 650 _2
- $a inhibitory cyklooxygenasy 2 $x analýza $7 D052246
- 650 _2
- $a preklinické hodnocení léčiv $7 D004353
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukotrien B4 $x antagonisté a inhibitory $x biosyntéza $7 D007975
- 650 _2
- $a inhibitory lipoxygenas $x analýza $7 D016859
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a neutrofily $x účinky léků $x metabolismus $7 D009504
- 650 _2
- $a rostlinné extrakty $x chemie $x farmakologie $7 D010936
- 650 _2
- $a léčivé rostliny $x chemie $7 D010946
- 650 _2
- $a chinony $x farmakologie $7 D011809
- 650 _2
- $a thymol $x analogy a deriváty $x farmakologie $7 D013943
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kutil, Zsofia $u -
- 700 1_
- $a Temml, Veronika $u -
- 700 1_
- $a Malik, Jan $u -
- 700 1_
- $a Kokoska, Ladislav $u -
- 700 1_
- $a Widowitz, Ute $u -
- 700 1_
- $a Pribylova, Marie $u -
- 700 1_
- $a Dvorakova, Marcela $u -
- 700 1_
- $a Marsik, Petr $u -
- 700 1_
- $a Schuster, Daniela $u -
- 700 1_
- $a Bauer, Rudolf $u -
- 700 1_
- $a Vanek, Tomas $u -
- 773 0_
- $w MED00180450 $t Natural product communications $x 1934-578X $g Roč. 8, č. 1 (2013), s. 105-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23472470 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20130710101237 $b ABA008
- 999 __
- $a ok $b bmc $g 987621 $s 822321
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 8 $c 1 $d 105-8 $i 1934-578X $m Natural product communications $n Nat Prod Commun $x MED00180450
- LZP __
- $a Pubmed-20130703